257871-22-0Relevant articles and documents
5-Aryl-pyrazolo[3,4-b]pyridazines: Potent inhibitors of glycogen synthase kinase-3 (GSK-3)
Witherington, Jason,Bordas, Vincent,Haigh, David,Hickey, Deirdre M. B.,Ife, Robert J.,Rawlings, Anthony D.,Slingsby, Brian P.,Smith, David G.,Ward, Robert W.
, p. 1581 - 1584 (2003)
Introduction of a nitrogen atom into the 6-position of a series of pyrazolo[3,4-b]pyridines led to a dramatic improvement in the potency of GSK-3 inhibition. Rationalisation of the binding mode suggested participation of a putative structural water molecule, which was subsequently confirmed by X-ray crystallography.
Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases
Bra?a, Miguel F.,Cacho, Mónica,García, M. Luisa,Mayoral, Elena P.,López, Berta,De Pascual-Teresa, Beatriz,Ramos, Ana,Acero, Nuria,Llinares, Francisco,Mu?oz-Mingarro, Dolores,Lozach, Olivier,Meijer, Laurent
, p. 6843 - 6854 (2007/10/03)
Pyrazolopyridazine 1a was identified in a high-throughput screening carried out by BASF Bioresearch Corp. (Worcester, MA) as a potent inhibitor of CDK1/cyclin B and shown to have selectivity for the CDK family. Analogues of the lead compound have been syn
Pyrazolopyridines and pyrazolopyridazines as antidabetics
-
Page/Page column 21, (2010/02/05)
The present invention includes compound of formula (I), or a derivative thereof, wherein Y is CH or N; R1 is unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted cycloalkenyl, unsubstituted or substituted aryl, aralkyl wherein the aryl and the alkyl moieties may each independently be unsubstituted or substituted, aralkenyl wherein the aryl, and alkenyl moieties may each independently be unsubstituted or substituted, unsubstituted or substituted heterocyclyl, or heterocyclylalkyl wherein the heterocyclyl and the alkyl moieties may each independently be unsubstituted or substituted; and R2 is unsubstituted aryl or unsubstituted or substituted or substituted heteroaryl. Additionally the present invention includes a process for preparing such a compound, a pharmaceutical composition containing such a compound, and the use of such a compound in medicine.